利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.043 秒)

    P53 binding T cell receptor molecules
    1.
    发明授权
    P53 binding T cell receptor molecules 有权
    P53结合T细胞受体分子

    公开(公告)号：US07456263B2

    公开(公告)日：2008-11-25

    申请号：US10163084

    申请日：2002-06-05

    申请人： Linda A. Sherman ,  Kimberlyn F. Card ,  Jon A. Weidanz ,  Hing C. Wong ,  Elizabeth L. Thomson

    发明人： Linda A. Sherman ,  Kimberlyn F. Card ,  Jon A. Weidanz ,  Hing C. Wong ,  Elizabeth L. Thomson

    IPC分类号： C07K16/30

    CPC分类号： C07K14/7051 ,  A61K38/00

    摘要： The invention provides T-cell receptor (TCR) molecules comprising a Vα chain and a Vβ chain that bind peptides derived from the p53 protein, preferably, the human p53 protein. The TCR molecules include both heterodimeric molecules and single chain molecules which specifically bind a sequence preferably spanning about amino acid positions 264-272 of the p53 protein displayed in the context of an HLA molecule, preferably, HLA-A2.1. Also disclosed are methods for making and using such TCR molecules. The invention has a wide spectrum of useful application including therapeutic uses and use in the detection of cells expressing p53 protein.

    摘要翻译： 本发明提供了包含Valpha链和结合来源于p53蛋白的肽优选人p53蛋白的Vbeta链的T细胞受体（TCR）分子。 TCR分子包括异源二聚体分子和单链分子，其特异性结合优选跨越在HLA分子，优选HLA-A2.1上下文中显示的p53蛋白的氨基酸位置264-272的序列。 还公开了制备和使用这种TCR分子的方法。 本发明具有广泛的有用应用，包括治疗用途和用于检测表达p53蛋白的细胞。

    P53 BINDING T CELL RECEPTOR MOLECULES
    2.
    发明申请
    P53 BINDING T CELL RECEPTOR MOLECULES 有权
    P53结合T细胞受体分子

    公开(公告)号：US20080269113A1

    公开(公告)日：2008-10-30

    申请号：US10163084

    申请日：2002-06-05

    申请人： Linda A. Sherman ,  Kimberlyn F. Card ,  Jon A. Weidanz ,  Hing C. Wong ,  Elizabeth L. Thomson

    发明人： Linda A. Sherman ,  Kimberlyn F. Card ,  Jon A. Weidanz ,  Hing C. Wong ,  Elizabeth L. Thomson

    IPC分类号： A61K38/17 ,  C07K14/715 ,  C12N5/06 ,  C07H21/04 ,  C12P21/06

    CPC分类号： C07K14/7051 ,  A61K38/00

    摘要： The invention provides T-cell receptor (TCR) molecules comprising a Vα chain and a Vβ chain that bind peptides derived from the p53 protein, preferably, the human p53 protein. The TCR molecules include both heterodimeric molecules and single chain molecules which specifically bind a sequence preferably spanning about amino acid positions 264-272 of the p53 protein displayed in the context of an HLA molecule, preferably, HLA-A2.1. Also disclosed are methods for making and using such TCR molecules. The invention has a wide spectrum of useful application including therapeutic uses and use in the detection of cells expressing p53 protein.

    摘要翻译： 本发明提供了包含Valpha链和结合来源于p53蛋白的肽优选人p53蛋白的Vbeta链的T细胞受体（TCR）分子。 TCR分子包括异源二聚体分子和单链分子，其特异性结合优选跨越在HLA分子，优选HLA-A2.1上下文中显示的p53蛋白的氨基酸位置264-272的序列。 还公开了制备和使用这种TCR分子的方法。 本发明具有广泛的有用应用，包括治疗用途和用于检测表达p53蛋白的细胞。

    Methods of assaying vaccine potency
    8.
    发明申请
    Methods of assaying vaccine potency 审中-公开
    测定疫苗效力的方法

    公开(公告)号：US20090233318A1

    公开(公告)日：2009-09-17

    申请号：US12380136

    申请日：2009-02-24

    申请人： Jon A. Weidanz

    发明人： Jon A. Weidanz

    IPC分类号： G01N33/53

    CPC分类号： G01N33/56977 ,  A61K39/0011 ,  A61K2039/605 ,  C07K14/7051 ,  C07K16/26 ,  C07K2317/32 ,  C07K2317/34

    摘要： The present invention is related to methods of assaying potency of a vaccine composition, wherein the potency is a pre-defined minimum level of potential biological activity for the vaccine composition. The method includes providing a vaccine composition and delivering same to an antigen presenting cell, wherein the vaccine composition is processed into peptides and the peptides are presented by MHC complexes on the cell surface. An agent, such as a T cell receptor mimic, that is reactive against a specific peptide/MHC complex is provided and reacted with the vaccine-treated antigen presenting cell, whereby the agent binds to the cell surface of the vaccine-treated antigen presenting cell if the specific peptide/MHC complex recognized by the agent is present on the cell surface. A density of the specific peptide/MHC complex on the surface of the vaccine-treated antigen presenting cell is measured by agent binding. The potency of the vaccine is then determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated antigen presenting cell.

    摘要翻译： 本发明涉及测定疫苗组合物效力的方法，其中效力是疫苗组合物潜在生物学活性的预定最低水平。 该方法包括提供疫苗组合物并将其递送至抗原呈递细胞，其中将疫苗组合物加工成肽，并且肽由细胞表面上的MHC复合物呈递。 提供对特定肽/ MHC复合物具有反应性的药剂，例如T细胞受体模拟物，并与疫苗处理的抗原呈递细胞反应，由此该药剂结合疫苗处理的抗原呈递细胞的细胞表面 如果试剂所识别的特异性肽/ MHC复合物存在于细胞表面。 疫苗处理的抗原呈递细胞表面上的特异性肽/ MHC复合物的密度通过试剂结合来测量。 然后基于疫苗处理的抗原呈递细胞表面上存在的特异性肽/ MHC复合物的测量密度来确定疫苗的效力。

    ANTIBODIES AS T CELL RECEPTOR MIMICS, METHODS OF PRODUCTION AND USES THEREOF
    10.
    发明申请
    ANTIBODIES AS T CELL RECEPTOR MIMICS, METHODS OF PRODUCTION AND USES THEREOF 审中-公开
    抗体作为细胞受体MIMICS，生产方法及其用途

    公开(公告)号：US20110293623A1

    公开(公告)日：2011-12-01

    申请号：US13155152

    申请日：2011-06-07

    申请人： Jon A. Weidanz

    发明人： Jon A. Weidanz

    IPC分类号： A61K39/395

    CPC分类号： A61K39/0011 ,  A61K2039/605 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/32 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

    摘要： The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest. An effective amount of the immunogen is then administered to a host for eliciting an immune response, and serum collected from the host is assayed to determine if desired antibodies that recognize a three-dimensional presentation of the peptide in the binding groove of the MHC molecule are being produced. The desired antibodies can differentiate the peptide/MHC complex from the MHC molecule alone, the peptide alone, and a complex of MHC and irrelevant peptide. Finally, the desired antibodies are isolated.

    摘要翻译： 本发明涉及产生识别与致瘤性或疾病状态相关的肽的抗体的方法，其中所述肽在HLA分子的上下文中显示。 这些抗体将模拟T细胞受体（TCR）的特异性，但具有较高的结合亲和力，使得该分子可用作治疗，诊断和研究试剂。 制备本发明的T细胞受体模拟物的方法包括鉴定感兴趣的肽，其中所述肽能够被MHC分子呈递。 然后，形成包含至少一个肽/ MHC复合物的免疫原，其中肽/ MHC复合物的肽是目的肽。 然后将有效量的免疫原施用于宿主以引发免疫应答，并测定从宿主收集的血清，以确定是否需要识别在MHC分子的结合槽中肽的三维呈现的所需抗体是 正在生产。 所需的抗体可以区分肽/ MHC复合物与单独的MHC分子，单独的肽以及MHC和无关肽的复合物。 最后，分离所需的抗体。